Related Experiment Video

Updated: Dec 31, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

990

Current issues and perspectives in PD-1 blockade cancer immunotherapy

Kenji Chamoto1, Ryusuke Hatae1, Tasuku Honjo2

  • 1Department of Immunology and Genomic Medicine, Kyoto University Graduate School of Medicine, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.

International Journal of Clinical Oncology
|January 5, 2020
PubMed

Insights

Programmed cell death 1 (PD-1) blockade therapy shows promise in cancer treatment but faces challenges with patient response and side effects. Further research into mechanisms and biomarkers is crucial for improving efficacy and safety in cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Programmed cell death 1 (PD-1) signal receptor blockade has transformed cancer therapy.
  • Current PD-1 blockade drugs face limitations including patient non-response, recurrence, and autoimmune side effects.

Purpose of the Study:

  • To investigate the mechanisms underlying PD-1 blockade therapy.
  • To identify novel biomarkers for predicting treatment response and monitoring adverse events.
  • To explore combination therapy strategies to enhance PD-1 blockade efficacy.

Main Methods:

  • This review synthesizes current research on PD-1 blockade mechanisms.
  • It analyzes clinical data regarding patient response and side effects.
  • It discusses the potential of combination therapies and biomarker development.

Main Results:

  • PD-1 blockade therapy has revolutionized cancer treatment but has significant limitations.
  • Patient non-response and autoimmune side effects remain major challenges.
  • Combination therapies and novel biomarkers are essential for improving outcomes.

Conclusions:

  • Addressing non-response and side effects is critical for advancing PD-1 blockade cancer immunotherapy.
  • Further research into mechanisms, biomarkers, and combination strategies is needed.
  • Optimizing PD-1 blockade therapy is central to improving cancer patient care globally.
Keywords:
BiomarkerCombination therapyImmune checkpoint inhibitorImmune metabolismImmune-related adverse event

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.1K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
894
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K